CMAX stock closed the session on 03 Mar 2026 at USD 0.42, putting the micro-cap CareMax, Inc. (CMAX) in an oversold-bounce setup after heavy pressure earlier this year. Volume finished at 772,036 shares versus a 30-day average near 1,220,672, showing reduced but present trading interest. CareMax trades on the NASDAQ in the United States and reports an enterprise value around USD 436,988,904.00. We use data-driven signals and Meyka AI analysis to frame a short-term bounce trade while noting weak fundamentals and elevated leverage.

CMAX stock price action and session detail

CareMax, Inc. (CMAX) closed at USD 0.42 on 03 Mar 2026 with unchanged intraday range of USD 0.42. The stock’s year high is USD 0.52 and year low is USD 0.4215, reflecting a very tight quoted spread. Market cap is USD 1,607,904.00 and traded volume was 772,036, below the average of 1,220,672, which is common during consolidation after sharp moves.

CMAX stock fundamentals snapshot

CareMax operates in Healthcare, Medical – Healthcare Information Services, and shows stretched fundamentals. EPS stands at -208.91, with no meaningful P/E. Revenue per share TTM is 201.47, cash per share is 17.58, and book value per share is 16.48. Debt to equity is 8.15, and current ratio is 0.42, indicating liquidity pressure despite sizeable cash per share metrics that reflect accounting scale differences.

CMAX stock technicals and oversold bounce setup

Technicals show extreme low nominal pricing with limited indicator data and ATR of 0.42. Price sits near the multi-month low and the stock’s 50-day average is 0.02 while the 200-day average is 1.64, underlining volatile history. An oversold bounce trade is plausible on intra-day mean reversion or catalyst-driven coverage. Traders should use tight stops given low liquidity and wide enterprise-value-to-sales dynamics.

Meyka AI rates CMAX with a score out of 100 and forecast

Meyka AI rates CMAX with a score of 60.54 out of 100 — Grade B, SUGGESTION: HOLD. This grade factors S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects USD 0.45 (monthly). Compared with the current price USD 0.4215, that implies an upside of 6.77%. Forecasts are model-based projections and not guarantees.

CMAX stock risks and catalysts

Key risks include negative operating margins, high debt ratios, and weak liquidity measures such as current ratio 0.42. Catalysts for a bounce would be improved earnings detail, contract wins, or broader sector momentum in Healthcare. The next earnings date is scheduled for 2025-05-07, which could provide a volatility trigger.

CMAX stock trading strategy and targets

For an oversold bounce strategy, consider small position sizes and tight risk controls. Short-term price targets: conservative USD 0.40, base USD 0.45 (Meyka AI monthly), optimistic USD 0.55 if momentum reappears. Stop-loss placement should reflect liquidity; a suggested stop is below USD 0.40 for short-term trades. Remember this is a micro-cap, so slippage can be material.

Final Thoughts

CareMax (CMAX) closed the NASDAQ session at USD 0.42 on 03 Mar 2026 and fits an oversold bounce profile for nimble traders. Fundamentals remain challenged with EPS -208.91, debt-to-equity 8.15, and current ratio 0.42, so any long exposure should be size-limited. Meyka AI’s forecast model projects USD 0.45, implying roughly 6.77% upside from the quoted level USD 0.4215; forecasts are model-based and not guarantees. We rate this a data-driven, short-term bounce idea rather than a fundamental rebound trade. Monitor volume, the May 07, 2025 earnings date, and Healthcare sector moves. Meyka AI provides this AI-powered market analysis platform perspective to help frame risk-managed actions; always validate with your own research.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.